Clinical TrialMay 5, 2026, 07:02 AM
Regeneron's Dupixent Shows Significant EoE Improvements in Phase 4 Trial
AI Summary
Regeneron and Sanofi presented positive results from the REMODEL Phase 4 trial for Dupixent in adult patients with eosinophilic esophagitis (EoE). The trial demonstrated significant and clinically meaningful improvements in esophageal distensibility and disease-related structural changes compared to placebo at week 24. These findings reinforce Dupixent's role as the leading biologic treatment for EoE by addressing underlying inflammation and symptoms.
Key Highlights
- Dupixent showed 1.30 mm placebo-corrected improvement in esophageal distensibility plateau (p<0.05).
- Dupixent achieved an 8% placebo-corrected improvement in esophageal distensibility plateau (p<0.05).
- Dupixent reduced disease-related structural changes by 4.96 points placebo-corrected (p<0.0001).
- Dupixent showed 0.71-point and 0.65-point placebo-corrected reductions in EoE-HSS grade and stage scores (p<0.0001).
- 59% of Dupixent patients achieved histological remission (≤6 eos/hpf) vs. 4% for placebo (p<0.0001).
- 78% of Dupixent patients achieved <15 eos/hpf vs. 4% for placebo (nominal p<0.0001).
- Overall adverse events were 62% for Dupixent and 48% for placebo, with no serious AEs.
Price Impact
More from REGN